Advertisement

Advanced Head and Neck Malignancy

  • Lori Wirth
  • Babar Sultan
  • Merrill S. Kies

Abstract

A computerized Ovid search of MEDLINE 1966-January 2006 was performed. The terms “postoperative therapy,” “adjuvant therapy,” and “head and neck cancer” were exploded and the resulting articles were cross-referenced, yielding 7643 articles limited to “human” and “English language.” These articles or abstracts were then reviewed to identify those that met the following inclusion criteria: 1) patient population with operable squamous cell carcinoma of the head and neck (SCCHN) with highrisk features, 2) intervention with a postoperative experimental arm (postoperative cisplatin with radiotherapy) versus a standard therapy arm (postoperative radiotherapy alone), 3) primary outcome measured in terms of progression- or disease-free survival, overall survival (OS), or locoregional (LR) control. The references of these articles were reviewed and manually cross-checked to ensure all applicable literature was included. This process yielded three randomized controlled trials (RCTs), a detailed analysis of which is presented below.

Keywords

Overall Survival Overall Response Rate Radiation Therapy Oncology Group Advanced Head Bone Marrow Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Johnson JT, Barnes EL, Myers EN, Schramm VL Jr, Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol 1981;107(12):725–729.PubMedGoogle Scholar
  2. 2.
    Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors of neck node metastasis. Clin Otolarygol Allied Sci 1982;7(3):185–192.CrossRefGoogle Scholar
  3. 3.
    Vikram B, Strong EW, Shah JP, Spiro R. Failure at the primary site following multimodality treatment in advanced head and neck cancer. Head Neck Surg 1984;6(3):720–723.CrossRefPubMedGoogle Scholar
  4. 4.
    Cooper JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85–03 and #88–24: targets for postoperative radiochemotherapy? Head Neck 1998;20(7):588–594.CrossRefPubMedGoogle Scholar
  5. 5.
    Vandenbrouck C, Sancho H, Le Fur R, Richard JM, Cachin Y. Results of a randomized clinical trial of preoperative irradiation versus postoperative in treatment of tumors of the hypopharynx. Cancer 1977;39(4):1445–1449.CrossRefPubMedGoogle Scholar
  6. 6.
    Strong MS, Vaughan CW, Kayne HL, et al. A randomized trial of preoperative radiotherapy in cancer of the oropharynx and hypopharynx. Am J Surg 1978;136(4):494–500.CrossRefPubMedGoogle Scholar
  7. 7.
    Tupchong L, Scott CB, Blitzer PH, et al. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73–03. Int J Radiat Oncol Biol Phys 1991; 20(1):21–28.PubMedGoogle Scholar
  8. 8.
    Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51(3):571–578.PubMedGoogle Scholar
  9. 9.
    Sanguineti G, Richetti A, Bignardi M, et al. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter phase III study. Int J Radiat Oncol Biol Phys 2005;61(3):762–771.PubMedGoogle Scholar
  10. 10.
    Rentschler RE, Wilbur DW, Petti GH, et al. Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas—a prospective, randomized study. J Clin Oncol 1987;5(2):278–285.PubMedGoogle Scholar
  11. 11.
    Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 1992;23(4):705–713.PubMedGoogle Scholar
  12. 12.
    Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355(9208):949–955.PubMedGoogle Scholar
  13. 13.
    Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36(5):999–1004.PubMedGoogle Scholar
  14. 14.
    Smid L, Budihna M, Zakotnik B, et al. Postoperative concomitant irradiation and chemotherapy with mitomycin C and bleomycin for advanced head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2003;56(4): 1055–1062.CrossRefPubMedGoogle Scholar
  15. 15.
    Haffty BG, Wilson LD, Son YH, et al. Concurrent chemoradiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys 2005;61(1):119–128.PubMedGoogle Scholar
  16. 16.
    Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350(19):1945–1952.CrossRefPubMedGoogle Scholar
  17. 17.
    Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937–1944.CrossRefPubMedGoogle Scholar
  18. 18.
    Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005;27(10):843–850.CrossRefPubMedGoogle Scholar

References

  1. 1.
    Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19(4):1088–1095.PubMedGoogle Scholar
  2. 2.
    Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(15):3562–3567.CrossRefPubMedGoogle Scholar
  3. 3.
    Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5(6):521–526.PubMedGoogle Scholar
  4. 4.
    Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10(8):1245–1251.PubMedGoogle Scholar
  5. 5.
    Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257–263.PubMedGoogle Scholar
  6. 6.
    Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002;20(6):1593–1599.CrossRefPubMedGoogle Scholar

References

  1. 1.
    Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006;6:28.CrossRefPubMedGoogle Scholar
  2. 2.
    Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355(9208):949–955.PubMedGoogle Scholar
  3. 3.
    Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21(1):92–98.CrossRefPubMedGoogle Scholar
  4. 4.
    Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91(24):2081–2086.CrossRefPubMedGoogle Scholar
  5. 5.
    Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16(4):1318–1324.PubMedGoogle Scholar
  6. 6.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567–578.CrossRefPubMedGoogle Scholar
  7. 7.
    Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated, hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95–06 Prospective Randomized Trial. J Clin Oncol 2005;23(6):1125–1135.CrossRefPubMedGoogle Scholar
  8. 8.
    Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy—results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50(5):1161–1171.PubMedGoogle Scholar
  9. 9.
    Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004;22(23):4665–4673.CrossRefPubMedGoogle Scholar
  10. 10.
    Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18(7):1458–1464.PubMedGoogle Scholar
  11. 11.
    Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338(25):1798–1804.CrossRefPubMedGoogle Scholar
  12. 12.
    Semrau R, Mueller RP, Stuetzer H, et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006;64(5):1308–1316.PubMedGoogle Scholar
  13. 13.
    Salvajoli JV, Morioka H, Trippe N, Kowalski LP. A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 1992;249(4):211–215.CrossRefPubMedGoogle Scholar
  14. 14.
    Zakotnik B, Smid L, Budihna M, et al. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report. Int J Radiat Oncol Biol Phys 1998;41(5):1121–1127.PubMedGoogle Scholar
  15. 15.
    Olmi P, Crispino S, Fallai C, et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003; 55(1):78–92.CrossRefPubMedGoogle Scholar
  16. 16.
    Bensadoun RJ, Benezery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006;64(4):983–994.PubMedGoogle Scholar
  17. 17.
    Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94–01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003;55(1):93–98.CrossRefPubMedGoogle Scholar
  18. 18.
    Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23(34):8636–8645.CrossRefPubMedGoogle Scholar
  19. 19.
    Posner MR, Haddad RI, Wirth L, et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004;31(6):778–785.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Lori Wirth
    • 1
  • Babar Sultan
    • 2
  • Merrill S. Kies
    • 3
  1. 1.Dana-Farber Cancer InstituteBostonUSA
  2. 2.Department of OtolaryngologyJohns Hopkins UniversityBaltimoreUSA
  3. 3.Head and Neck Medical Oncology, M.D. AndersonHoustonUSA

Personalised recommendations